FORT LEE, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Alpharma Inc. , a leading global specialty pharmaceutical company, announced today that senior management of Alpharma's Pharmaceutical business will discuss the market potential for abuse deterrent pain products and the company's clinical program designed to address this opportunity at the Oppenheimer Pain Conference on Tuesday March 6, 2007 at 9:45 AM Eastern Standard Time at the Flatotel in New York City.
This presentation will be audio webcast live and can be accessed through Alpharma's website, http://www.alpharma.com.
An archived version will be available for 90 days after the live presentation and can be accessed at the same location.
Alpharma press releases are also available at our website: http://www.alpharma.com.
Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded franchise in the chronic pain market with its morphine-based extended release KADIAN(R) product. In addition, Alpharma is among the world's leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.
Alpharma Inc.CONTACT: Kathleen Makrakis, VP, Investor Relations, of Alpharma Inc.,+1-201-228-5085, kathleen.makrakis@alpharma.com
Web site: http://www.alpharma.com/
